FORTE BIOSCIENCES FBRX 深 沪
等待开盘 02-06 09:30:00 美东时间
28.81
-3.230
-10.08%
华盛通- 最 高32.07
- 今 开31.95
- 成交量 19.75万股
- 最 低 28.09
- 昨 收 32.04
- 总市值 3.58亿
- 52周最高 35.62
- 市盈率 静 --
- 换手率 1.59%
- 52周最低 4.90
- 委 比 -94.87%
- 总股本 1243.29万
- 历史最高 6732.375
- 量 比 0.67
- 振 幅 12.42%
- 历史最低 4.90
- 每 手 1
- 风险率 7.12%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股牛股 | 存储再度狂飙！Sandisk大涨逾15%；生物技术公司TWST涨约14%，Q1业绩超预期
存储再度狂飙！Sandisk大涨逾15%，伯恩斯坦上调目标价至1000美元；生物技术公司TWST涨约14%，Q1业绩超预期；欧朋涨超13%，此前上调Q4收入预期指引>>
02-03 15:29
美股牛股 | 私人航空公司UP单日暴涨46%！One Stop大涨29%，获美军预生产订单
私人航空公司UP单日暴涨46%！One Stop股价涨29%，获美军预生产订单；BIOA涨逾27%，核心在研药获突破进展>>
01-13 17:24
美股大行评级 | 安捷伦科技、Keysight、先科电子获多家大行上调目标价；摩根大通下调亿航智能评级至"中性"，目标价下调至13美元
今日重点评级关注：HC Wainwright & Co.：维持BiomX"买入"评级，目标价从15美元升至26美元；Clear Street：维持Diversified Energy"买入"评级，目标价从23美元升至25美元
2025-11-26 10:07
Evercore ISI Group Initiates Coverage On Forte Biosciences with Outperform Rating, Announces Price Target of $65
Evercore ISI Group analyst Gavin Clark-Gartner initiates coverage on Forte Biosciences (NASDAQ:FBRX) with a Outperform rating and announces Price Target of $65.
2025-11-25 20:56
美股大行评级 | Stifel上调特斯拉目标价升至508美元；多家大行上调Vita Coco目标价最高至58美元
今日重点评级关注：HC Wainwright & Co.：维持Oncolytics Biotech"买入"评级，目标价从5美元升至10美元；HC Wainwright & Co.：维持Barinthus Biotherapeutics"买入"评级，目标价从3美元升至4美元
2025-11-18 15:28
Chardan Capital Maintains Buy on Forte Biosciences, Maintains $61 Price Target
Chardan Capital analyst Daniil Gataulin maintains Forte Biosciences (NASDAQ:FBRX) with a Buy and maintains $61 price target.
2025-11-17 20:50
Forte Biosciences Q3 EPS $(0.99) Beats $(1.06) Estimate
Forte Biosciences (NASDAQ:FBRX) reported quarterly losses of $(0.99) per share which beat the analyst consensus estimate of $(1.06) by 6.43 percent. This is a 78.19 percent increase over losses of $(4.54) per share from
2025-11-14 22:13
Forte Biosciences Highlights FB102's Efficacy in Celiac Disease at Tampere Symposium, Underscoring Histological Protection and Symptom Relief in Phase 1b Study
Additional data continues to support highly differentiated profile for FB102 in celiac diseaseForte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune
2025-09-15 21:09
Chardan Capital Maintains Buy on Forte Biosciences, Maintains $61 Price Target
Chardan Capital analyst Daniil Gataulin maintains Forte Biosciences (NASDAQ:FBRX) with a Buy and maintains $61 price target.
2025-08-15 20:11
Forte Biosciences Announces Public Offering of Shares
Forte Biosciences ( ($FBRX) ) just unveiled an update. On June 24, 2025, Forte ...
2025-06-26 05:19
